Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Mangalam Drugs and Organics Ltd (MADR)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
100.30 -0.40    -0.40%
03:33:11 - Real-time Data. Currency in INR ( Disclaimer )
Type:  Equity
Market:  India
ISIN:  INE584F01014 
S/N:  MANGALAM
  • Volume: 11,636
  • Bid/Ask: 100.30 / 100.55
  • Day's Range: 100.25 - 101.90
Mangalam Drugs Organics 100.30 -0.40 -0.40%

Mangalam Drugs and Organics Ltd Company Profile

 
Get an in-depth profile of Mangalam Drugs and Organics Ltd, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

479

Equity Type

ORD

Mangalam Drugs & Organics Limited manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. It offers a range of API products, which include Acyclovir, Amodiaquine, Artemether, Artesunate, Atazanavir Sulfate, Bisoprolol Fumarate, Chloroquine Phosphate, Dihydroartemisinin, and Dolutegravir Sodium; Efavirenz, Emtricitabine, Furosemide, Hydroxychloroquine Sulphate, Lumefantrine, and Nimesulide; Nitrofurantoin Anhydrous and Monohydrate; Primaquine and Piperaquine Phosphate; Pregabalin, Pyrimethamine, Pyronaridine Tetraphosphate, and Sulfadoxine; and Tenofovir Alafenamide Hemifumarate and Disoproxil Fumarate. The company also offers intermediates comprising 2-Dibutylamino-1-(2,7-dichloro-9H-fluorine-4-yl)-ethanol; 4,6-Dichloro-5-methoxy pyrimidine; 4,7 Dichloroquinoline; Ortho phenoxy methane sulfonanilide; and Tenofovir Alafenamide Base and Disoproxil Base. In addition, it offers specialty chemicals, such as Menthol; 2,3-Dihydrophthalazine-1, 4-dione; and 4-cynoethyl-2-methyl phenol. Further, the company’s products under development include Tafenoquine Succinate, Bictegravir Na, Favipiravir, and Molnupiravir; and Elvitegravir, Cobicistat, Daclatasvir dihydrochloride, Ledipasvir, and Velpatasvir. The company was incorporated in 1972 and is based in Mumbai, India.

Contact Information

Address Rupam Building 3rd Floor
239, P D’ Mello Road Near GPO Mumbai,400001
India
Phone 91 22 6261 6200
Fax 91 22 6261 9090

Top Executives

Name Age Since Title
Brijmohan Murlidhar Dhoot 72 2015 Whole-Time Director
Govardhan Murlidhar Dhoot 70 1996 Chairman & MD
Nidhi Shantanu Mundada 35 2018 Non-Executive Independent Director
Rukmesh Prabhukumar Dhandhania 44 2017 Independent Director
Rakesh Kishinchand Milwani - 2022 Non-Executive Non- Independent Director
Praveen Saxena 68 2021 Independent Non-Executive Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

MADR Comments

Write your thoughts about Mangalam Drugs and Organics Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Praveen Nakod
Praveen Nakod Jun 29, 2020 12:05PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
When will can we get earning report
Praveen Nakod
Praveen Nakod Jun 18, 2020 8:12AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
At what price can we bye
Datta Nagari
Datta Nagari Jun 18, 2020 8:12AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
150
KEKIN patel
KEKIN patel May 07, 2020 1:19AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
still i think littel correction will come, but its good time to buy
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email